As clinical evidence supporting GLP-1 medications for weight loss continues to mount, and as federal policy discussions around obesity treatment expand, more states are reconsidering whether Medicaid should cover weight loss drugs
Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People With Type 2 Diabetes: A Randomised, Double-Blind, Placebo and Active-Controlled, Parallel-Group, Phase 2 Trial
Manuscript submission to peer review journal in progress
But because supplements are so unregulated, you can never really be completely sure whats in them
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Our protocol goes far beyond the script, combining unlimited access to expert providers, personalized nutrition support, app-based tracking, and a connected patient community. In a retrospective analysis of 1,131 patients treated with the GLP-1 drug semaglutide, combined with individualized medical oversight, patients lost an average of 45.9 pounds (19.5% total body weight loss) at 52 weeks, with those extending to 68 weeks achieving an average total weight loss of 46.9 pounds (21.8%)
